Skip to content

Cadence Research & Consulting

  • Services
  • Insight
  • About
  • Contact

news

Posted
April 23, 2018
Comments
0 Responses

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

  • Facebook
  • LinkedIn
  • Terms of Use
  • Privacy Policy
  • About
  • Contact
  • Blog

Recent Posts

  • Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer
  • Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma
  • Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  • Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC
  • Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer